Transaction in Own Shares

Summary by AI BETAClose X

Hikma Pharmaceuticals Plc has announced the repurchase of 34,554 ordinary shares between June 22, 2026, and June 26, 2026, as part of its $250 million share buyback program. These shares were acquired at prices ranging from 1,469.00 to 1,476.00 pence, with a volume-weighted average price of 1,473.17 pence for the XLON trading venue. The company intends to cancel these repurchased shares, and since the program's inception on February 26, 2026, a total of 9,666,177 shares have been bought back for £130,823,465.52. Following these transactions and cancellations, Hikma will have 212,220,276 ordinary shares in issue.

Disclaimer*

UK 100

Latest directors dealings